Compare Neurocrine Biosciences Inc (NBIX) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while Direxion Daily S&P 500 Bull 3X Shares trades at $282.33. The key difference: Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | SPXL | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $185.50 | $301.38 |
52-Week Low | $123.10 | $170.20 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
SPXL, a leveraged ETF tracking the S&P 500, trades at $285.5, down 1.67% amid broader market caution. Technical indicators show a neutral overall signal with bullish moving averages, while support sits at $284 and resistance at $289. Recent news highlights market resilience despite geopolitical tensions and high valuations, with the S&P 500 up 13% over six months amid Iran conflicts.
The outlook remains mixed: AI-driven earnings growth supports further gains, but elevated valuations and Fed rate risks pose headwinds. Investors face volatility from oil prices and trade policies, yet long-term index fund strategies are favored by analysts targeting S&P 500 levels near 8,000.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
